The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.
Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.
This systematic review and meta-analysis assessed the burden of micronutrient deficiencies among patients with type 2 diabetes (T2D), analyzing 132 studies with 52,501 participants. Micronutrient deficiencies in T2D were 45.30%, with vitamin D (60.45%), magnesium (41.95%), and B12 (28.72%) most common. Women were more affected.
The study provides a comprehensive analysis of diabetes trends among adolescents aged 10–24 years. Using data from the Global Burden of Disease (GBD) 2021 study, it estimates the prevalence, disability-adjusted life years (DALYs), and risk factors for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) across 204 countries and territories. The findings reveal a significant increase in the global burden of adolescent diabetes, with 3.4 million living with T1DM and 14.6 million with T2DM in 2021. By 2030, these numbers are projected to rise to 3.7 million and 20.9 million, respectively.
A recent study examined the effects of combining the diabetes medication dapagliflozin with a calorie-restricted diet on achieving remission of type 2 diabetes. Conducted at 16 centers in China, the randomized, double-blind, placebo-controlled trial involved 328 patients with type 2 diabetes, aged 20-70, who were either overweight or obese. Participants received either dapagliflozin (10 mg/day) or a placebo with a 500-750 kcal/day diet.
